|
 |
European BioPharmaceutical Review
|
| In the midst of war, these are uncertain times to be going about the daily business of biotech with stock markets initially surging on the news and then reacting unpredictably to specific developments in the conflict. Given the consistently poor market conditions over the last two years, many of the smaller private companies will probably not see much difference in terms of the environment. There is still next to no short-term scope to access funding via the public markets, which continue to exert downward pressure on valuation of private companies, and maintain the high-level scrutiny by venture capital investors in private funding rounds. |
Read full article >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
Industry Events |
 |
Clinical Trials in CNS
25-26 November 2008, Copthorne Tara Hotel, London, UK
SMi present their 7th annual conference… Clinical Trials in CNS 25th to 26th November 2008, Copthorne Tara Hotel, London, UK
More info >> |
|
 |
News and Press Releases |
 |
Azopharma Product Development Group, Inc
HOLLYWOOD, Fla. – Azopharma Product Development Group, Inc. (“Azopharma”) announced today the addition of innovative state-of-the-art equipment at its formulation and manufacturing division, ApiCross Drug Delivery Technologies in Hollywood, Florida. The most recent acquisition is the MG Futura Capsule Filler which delivers the latest in capsule filling technology. The company has also added a Bausch & Strobel Aseptic Filling Isolator, equipment that is ground-breaking in the powder filling process. These additions support our previously implemented XcelodoseTM powder micro-dosing system. With these technologies, Azopharma is able to provide its clients with all forms of the capsule filling process. The new equipment is part of Azopharma’s recent manufacturing expansion which includes 17 new manufacturing suites for GMP, cytotoxic and aseptic products...
More info >> |
|
 |
